Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 3Other hematologic neoplasm 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 27Burkitt Lymphoma 18Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 11Leukemia, Biphenotypic, Acute 7Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 5Leukemia, Myeloid, Acute 5Lymphoma 4Leukemia 4Blast Crisis 4Recurrence 3Myelodysplastic Syndromes 3Leukemia, Plasma Cell 3Leukemia, Myelomonocytic, Chronic 3Hodgkin Disease 3Hematologic Neoplasms 3Vomiting 2Multiple Myeloma 2Lymphoma, Non-Hodgkin 2Lymphoma, Mantle-Cell 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2Lymphoma, B-Cell, Marginal Zone 2Leukemia, Myeloid, Accelerated Phase 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Leukemia, Lymphocytic, Chronic, B-Cell 2Leukemia, Hairy Cell 2Down Syndrome 2Waldenstrom Macroglobulinemia 1Testicular Neoplasms 1Testicular Germ Cell Tumor 1

Interventions

Dexamethasone 3filanesib 2Steroids 2Injections, Subcutaneous 2Granulocyte Colony-Stimulating Factor 2Filgrastim 2pomalidomide 1ixazomib 1dexamethasone acetate 1dexamethasone 21-phosphate 1auricularum 1Proteasome Inhibitors 1Peripheral Blood Stem Cell Transplantation 1Panobinostat 1Melphalan 1Gemcitabine 1Calcium Dobesilate 1Busulfan 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Plasmacytoma × dexamethasone 21-phosphate × Other hematologic neoplasm × Clear all
NCT02547662 2023-10-30

Pomalidomide, Ixazomib Citrate, and Dexamethasone in Treating Patients With Previously Treated Multiple Myeloma or Plasma Cell Leukemia

Mayo Clinic

Phase 2 Completed
17 enrolled 13 charts
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma, Plasmacytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡